Maruoka Y, Ohno Y, Kato T, Hirose A, Tatsuno T, Nakamura M
Research Laboratories, Sumitomo Pharmaceuticals Co., Ltd., Osaka, Japan.
Jpn J Pharmacol. 1993 Aug;62(4):419-22. doi: 10.1254/jjp.62.419.
The effects of SM-9018, a potential atypical neuroleptic, on monoamine metabolism were studied in rats. SM-9018 dose-dependently increased the levels of 3,4-dihydroxyphenylacetic acid (DOPAC) and homovanillic acid (HVA) in the cerebral cortex and striatum without affecting the levels of 5-HT, norepinephrine and their metabolites. This action persisted for 8 hr with a maximum effect at 1-2 hr. The SM-9018-induced increase of dopamine (DA) turnover, as indexed by HVA/DA and DOPAC/DA ratios, was comparable in the cerebral cortex and striatum, whereas the typical neuroleptic haloperidol preferentially enhanced the striatal DA turnover. These findings suggest that SM-9018, unlike haloperidol, increases DA turnover to a similar extent both in the cerebral cortex and striatum.
在大鼠中研究了潜在的非典型抗精神病药物SM - 9018对单胺代谢的影响。SM - 9018剂量依赖性地增加了大脑皮层和纹状体中3,4 - 二羟基苯乙酸(DOPAC)和高香草酸(HVA)的水平,而不影响5 - 羟色胺、去甲肾上腺素及其代谢物的水平。这种作用持续8小时,在1 - 2小时时达到最大效应。以HVA/DA和DOPAC/DA比率为指标,SM - 9018诱导的多巴胺(DA)周转增加在大脑皮层和纹状体中相当,而典型抗精神病药物氟哌啶醇则优先增强纹状体DA周转。这些发现表明,与氟哌啶醇不同,SM - 9018在大脑皮层和纹状体中增加DA周转的程度相似。